Rein Therapeutics (RNTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Jun, 2026Executive summary
Annual meeting scheduled for July 20, 2026, to be held online at 9:00 AM ET.
Proxy materials and annual report are available online for review and voting.
Shareholders are encouraged to vote electronically and can opt for electronic delivery of future materials.
Voting matters and shareholder proposals
Election of two Class III directors: Reinhard J. Ambros, Ph.D., and Josef H. von Rickenbach.
Proposal to increase authorized shares of common stock.
Ratification of CBIZ CPAs P.C. as independent registered public accounting firm.
Advisory vote to approve named executive officer compensation.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and proposals listed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Rein Therapeutics
- Q2 net loss narrowed, $57.5M raise extends cash runway, and Phase 2 LTI-03 trial on track.RNTX
Q2 2026 - All agenda items, including director elections and share authorization, were approved.RNTXAGM 2026
- Virtual meeting to vote on directors, share increase, auditor, and executive pay; board supports all.RNTXProxy filing
- Board recommends voting for all proposals, including director elections and share increase.RNTXProxy filing
- Q1 2026 net loss was $5.8M; cash and new equity expected to fund operations into 2028.RNTXQ1 2026
- Biopharma seeks $48M via Nasdaq IPO to advance IPF drug, repay debt, and fund operations.RNTXRegistration filing
- LTI-03 advances as a promising, safe IPF therapy with dual antifibrotic and regenerative action.RNTXCorporate presentation
- LTI-03 shows strong early safety and efficacy signals for IPF, targeting a major unmet market.RNTXCorporate presentation
- Net loss was $49.9M in 2025; LTI-03 Phase 2 trial ongoing, but cash only funds operations into Q2 2026.RNTXQ4 2025